bg-country-switch
Key figures

The HARTMANN GROUP, an internationally leading medical device company.

HARTMANN at a glance

We have offices in over 35 countries around the world, but our products are available in around 100 countries through a network of distributors.

HARTMANN is a leading international manufacturer of medical and hygiene products.

In a world where health is becoming an increasingly important matter and is managed more professionally, we offer our customers simple and effective solutions for the benefit of the patients. This is expressed in our brand promise of “Going further for health”. Professional solutions for wound treatment, incontinence hygiene and infection prevention form the core of our portfolio.

In 2019, we employed 11,096 staff worldwide and generated sales of EUR 2,19 million.

The HARTMANN solutions

In line with internal management, the HARTMANN GROUP's business activities are reported on by business segments which are arranged by product range focus, i.e. Wound, Incontinence and Infection Management as well as Other Group Activities, primarily including the activities of the Group companies, KNEIPP, KOB and CMC.

Share of total sales by business segment

Share of total sales by business segment 2019
in EUR million and percent (2019)

Within the Incontinence Management segment, sales increased by 0.8% to €708.2 million. The main drivers of the growth were primarily customized product solutions for outpatient treatment. MoliCare® Mobile, the pull-up pants for people on the move, was again the biggest driver of sales during the reporting year and the engine of growth in this business segment. Skincare products under the MoliCare® Skin brand and shaped MoliCare® Pads also performed well.

Sales revenues in the Wound Management segment in 2019 increased 6.1% compared with the previous year, to EUR 503.3 million. During the reporting year, modern wound treatment concepts such as super-absorbent wound dressings were successful drivers of growth. Innovative brands such as Zetuvit® Plus Silicone Border encountered a high level of acceptance among experts. Vivano®, the system solution for vacuum wound treatment, also performed well. In relation to traditional dressing materials, HARTMANN was able to hold up particularly strongly on the market with its post-operative dressings. The July 2019 acquisition of a leading manufacturer of silicone coatings, Safran Coating S.A.S. (now renamed Advanced Silicone Coating S.A.S.), enables HARTMANN to make further innovations in modern wound management.

The Personal Healthcare area, which also belongs to the Wound Management segment, benefited from the growth in sales in relation to the innovative Veroval® blood-pressure monitors.

In the Infection Management segment HARTMANN achieved 2.1% sales growth to EUR 515.9 million. The wide range of disposable instruments and gloves benefited from higher demand. Hand and surface sterilizers marketed under the Sterillium® brand similarly ensured a good rate of growth in the Infection Management segment. Alongside the classic Sterillium® Med for professional users, there was again growing customer acceptance of the Sterillium® Protect & Care range aimed at end users.

During the 2019 reporting year, results for the segment declined to EUR 21.4 million, largely due to the impact of price pressures in the sales markets for the disinfection sector, higher raw materials prices for examination gloves and through one-off expenses in connection with the suspension of the unprofitable business with customized full kits in Australia.

With an increase of 5.2%, there have been pleasing growth trends from the Other Group Activities segment. As of the end of 2019, sales across the group stood at EUR 464.8 million. The traditional brand Kneipp® has for over 125 years stood for effective, innovative and natural products for wellbeing and health based on the holistic teaching of Sebastian Kneipp. The attractive positioning of the brand and innovative ranges again led in the 2019 financial year to high demand from trade and end customers. In the main sales market of Germany in particular, the KNEIPP Group has grown in all product categories. Japan has continued to be a significant sales market for the company. The CMC Group is among Europe's leading suppliers of own brands for the trade in the areas of cosmetic cotton-wool pads and personal hygiene products. With these main drivers of sales, the CMC Group showed solid growth during the reporting year. The Other Group Activities segment recorded a EUR 4.7 million decline to EUR -9.6 million in EBIT during the reporting year.

Share of total sales by region

Share of total sales by region 2019
in EUR million and percent (2019)

During the reporting year, the HARTMANN GROUP increased its sales both in Germany and abroad. While domestic sales revenues rose by 2.2% to EUR 716.5 million, the revenues abroad climbed by 3.7% to EUR 1,470.3 million. The Company's organic growth achieved 2.2% in Germany and 3.2% abroad. At 67.2%, the proportion of business conducted outside Germany was slightly above the previous year's level.

In Europe, the Group recorded sales totaling EUR 1,951.3 million. This equates to an increase of 3.2% compared with the previous year. In the European markets excluding Germany, HARTMANN achieved growth in 2019 of 3.8% to EUR 1,234.8 million.

In the past financial year, customer sales in the Central European region rose moderately by 3.0% to EUR 897.4 million. The rise in sales in Germany, the main sales market, was in particular a result of positive performance in Wound Management and Other Group Activities.

In the countries of Western and Southern Europe, sales increased by 2.4% to EUR 676.5 million. HARTMANN was again able to achieve growth in its core medical segments in France, the group's second-largest sales market.

In Eastern Europe sales grew by 5.0% to EUR 287.5 million. Even in the area of Northern Europe HARTMANN was able to further improve its market position.

During the reporting year HARTMANN achieved sales growth of 2.9% in the markets outside Europe. With a rise of 5.6%, it performed above average in the region of Africa, Asia and Oceania.

In the region of America, we had to accept a decline in sales as a result of adjustments of the commercial portfolio.

Performance indicators

With a 3.2% increase in sales to EUR 2,186.8 million, the HARTMANN GROUP maintained its course for growth in 2019 despite difficult market conditions.

At EUR 104.4 million, EBIT was within the forecast range and below that of the previous year.

in EUR million 20182019Year-on-year
change
in %
Earnings
Sales revenues2,119.1
2,186.73.2
Of which outside Germany in %66.967.20.4
Consolidated net income83.862.9-24.9
Net return on sales in % 4.02.9
-27.2
Cost of materials920,0946,82.9
Personnel expense552,0578,54.8
EBIT DA193,5210,4
8.7
Return on EBIT DA in %9.19.65.4
depreciation/amortization on
tangible and intangible assets
70,3
106,0
50.7
EBIT123,2104,4-15.3
Return on EBIT in %5.8
4.8
-17.9
Cash-Flow156,7191,021.9
Free-Cash-Flow79,2
69,0
-12.9
Balance Sheet
Balance Sheet total1,499,3031,609,3577.3
Non-current assets645,5
749,0
16,0
Investments in tangible and
intangible assets 2)
84,9
107,0
26.1
Current assets853,8828,3-3.0
Equity capital and reserves923,1932,41.0
Equity/asset ratio in %61.6
57.9
-5.9
Return on equity in %9,1
6.7
-25.6
Net Financial Status104,5
33,5-68.0
Employees as at Dec. 31 1)11.02711.0963.2

1) Excluding staff on parental leave and PAUL HARTMANN AG Management Board members

2) Excluding investments from acquisitions like goodwill

In the 2019 financial year, the HARTMANN GROUP was again able to increase sales in all segments despite more challenging market conditions. As expected, there was moderate growth in sales of 3.2% to EUR 2,186.8 million. At the same time, the above-average growth in the Wound Management and Other Group Activities segments had a positive impact. Exchange rates, divestments and acquisitions had only minor effects during the reporting year, so organic growth stood at 2.8%.

In 2019, the HARTMANN GROUP's EBIT stood at EUR 104.4 million, compared with previous year EUR 123.2 million. This equates to a return on EBIT of 4.8%, after 5.8% the previous year. This performance results largely from non-operative measures to focus portfolios, particularly in relation to the SANIMED Group and the discontinuation of unprofitable business with customized full kits in Australia. In addition, regulatory costs associated with implementation of the new EU Medical Devices Regulation (MDR) also impacted the results during the reporting year negatively.

Through a multi-year transformation program launched during the 2019 financial year, HARTMANN is promoting sustainable profitability and organic growth in the strategic product groups and customer segments. The agreement made at the end of 2019 to sell the SANIMED Group stems from this focusing of the HARTMANN GROUP. As a result of this decision, the assets and liabilities held for sale were required, under IFRS 5, to be disclosed separately on the balance sheet and the SANIMED Group's longterm assets had to be revalued, which led to an impairment of EUR 9.5 million in EBIT. The financial result came to EUR -6.3 million, compared with EUR -2.5 million the previous year. This deterioration is attributable to the interest-rate effect from the first-time application of the IFRS 16 accounting standard and the associated recognition of lease liabilities. The income tax expenses came to EUR 35.1 million compared with EUR 36.9 million the previous year. The 5.2-percentage-point higher tax ratio of 35.8% is largely influenced by non-tax-effective impairments in connection with the valuation of the SANIMED Group under IFRS 5. The consolidated net income fell compared with the previous year by 20.8% to EUR 62.9 million.